Oklo shares have climbed for five consecutive trading sessions, delivering a cumulative gain of 36% over that span. This surge added roughly $3.9 billion in market value, lifting the company’s capitalization to about $15 billion. Investors attribute the momentum to a combination of strategic partnerships and growing enthusiasm for advanced nuclear solutions in power-hungry industries.

Oklo announced it has signed an Other Transaction Agreement with the U.S. Department of Energy to design, build and operate a radioisotope pilot plant under the Reactor Pilot Program. The facility will be managed by Oklo’s subsidiary, Atomic Alchemy, and will produce medical and research radioisotopes currently sourced mainly from overseas. While financial terms were not disclosed, the agreement marks Oklo’s transition from planning into active execution and is expected to generate critical data for future commercial deployments.

As demand for electricity in artificial intelligence data centers soars, small modular reactors are gaining favor as a reliable, low-carbon power source. Oklo is positioned alongside a handful of peers to benefit from policy incentives under the Trump Administration’s energy strategy. The company’s reactor design, optimized for compact footprints and scalable deployment, aligns with the needs of hyperscale computing campuses seeking uninterrupted baseload power.

Oklo’s fast reactor architecture leverages decades-old fuel cycle technologies, enabling safer operation and the potential to recycle spent nuclear material. CEO Jacob DeWitte has emphasized that pilot-scale operations will streamline regulatory approvals and de-risk commercial rollouts. With one site use permit already granted by the Department of Energy and preliminary fuel allocations secured, Oklo is advancing toward its first combined license application for a full-scale plant.